131802-89-6Relevant academic research and scientific papers
Method for selectively preparing hydroquinone monoether compound or quinol compound (by machine translation)
-
Paragraph 0034-0039; 0050-0052; 0067-0068, (2020/12/30)
The method comprises the following steps: taking an organic boric acid compound and a p-benzoquinone compound as a reaction raw material, under the action of a copper catalyst, selectively reacting to obtain a hydroquinone monoether compound or a quinol compound. Compared with the prior art, the method disclosed by the invention adopts a one-pot reaction, can selectively obtain two products through solvent control, is suitable for preparing various types of hydroquinone monoether compounds and quinol compounds, and has wide applicability. The substrate functional group is high in tolerance and wide in substrate range. The raw material and the catalyst are cheap and easily available, the reaction conditions are mild, the reaction solvent is green and environment-friendly, the post-treatment is simple, and the yield and purity of the product are high. The preparation method is convenient. The method is rapid and efficient, and has a good application prospect in drug molecule synthesis. (by machine translation)
1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES
-
Page/Page column 31, (2009/04/25)
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I), wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
LEUKOTRIENE B4 ANTAGONISTS
-
, (2008/06/13)
This invention provides certain 1,2,4,5 substituted benzene derivatives containing "acid" substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B 4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes. "
